![]() |
XNCR | Xencor Inc |
Pharmaceutical Preparations |
Book value per $ invested | $ 1.99 |
Leverage | 29.22% |
Market Cap | $ 996.9m |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -235.6m |
Margin | -289.84% |
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.